Research programme: ZW 33 - Zymeworks

Drug Profile

Research programme: ZW 33 - Zymeworks

Alternative Names: Biparatopic HER2 antibody

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zymeworks
  • Class Bispecific antibodies; Proteins
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Gastric cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gastric-cancer in Canada
  • 18 Aug 2016 Research programme: ZW 33 - Zymeworks receives Orphan Drug status for Ovarian cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top